Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ANTX vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANTX Captures Overall Composite Edge (40.5 SELL vs 52.3 HOLD), While OVID Leads 4–1 on Growth & Valuation Pillars

ANTX Overall Winner 6-Pillar Tally: ANTX 1 – 4 OVID (1 Tie) Matrix Metrics: ANTX 3 – 6 OVID

As of Nov 20, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (40.5/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 3–6 (led by Options & Positioning), while OVID wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.08 (N/M Forward P/E, 0.0% operating margin) versus OVID at $2.20 (1.8x Forward P/E, -4693.7% operating margin).

  • Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. ANTX 40.5/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY).
  • Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 61.8); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANTX vs OVID
ANTX NASDAQ Head-to-Head Winner
AN2 Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$5.08
-2.68% 1D
Market Cap $198.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.74β · 99% Vol
Unified Composite Score
40.5 / 100 SELL
Tech 15.0 Fund 44.0 Flow 66.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $4.38 · SMA50: $4.51
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.04β · 97% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $2.49 · SMA50: $2.46

6-Pillar Scorecard Institutional Category Breakdown (ANTX 1 – 4 OVID)

Columns: Metric · ANTX · OVID
1. Valuation Multiples OVID
Forward P/E N/M 1.8x
Trailing P/E N/M 1.8x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OVID
Revenue Growth (YoY) +0.0% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.5M
Market Cap $198.1M $424.6M
3. Profitability & Quality OVID
Gross Margin N/A 100.0%
Operating Margin 0.0% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -51.3% -35.4%
4. Balance Sheet & Cash Flow OVID
Cash Generation (TTM) -$30M -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.99 Book/Sh · -51.3% ROE $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANTX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 306.5% (92nd %ile) 11.7% (<1st %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANTX (3) vs OVID (6)
Institutional Metric ANTX OVID Criterion Row Edge
Market Capitalization
Scale
$198.1M $424.6M Larger Scale OVID
Trailing P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
+0.0% -88.3% Higher Growth ANTX
Operating Margin (TTM)
Profitability
0.0% -4693.7% Higher Margin ANTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-51.3% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
66% ($1–$7) 52% ($1–$3) Stronger Trend ANTX
Beta / 30D Volatility
Risk Regime
0.74β · 99% Vol 1.04β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
40.5 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$30M ($1.99 Book/Sh · -51.3% ROE) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANTX +46.73 pp
ANTX: +39.56% · OVID: -7.17%
3M Horizon ANTX +12.22 pp
ANTX: -9.77% · OVID: -21.99%
6M Horizon ANTX +15.67 pp
ANTX: +4.74% · OVID: -10.93%
1Y Horizon ANTX +298.49 pp
ANTX: +370.37% · OVID: +71.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANTX vs OVID. Trailing 12-month operating profitability (ANTX 0.0% vs OVID -4693.7%) and valuation multiples (ANTX N/M vs OVID 1.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ANTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-51.3% · N/M
OVID ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-4693.7%
ROE / Fwd P/E-35.4% · 1.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANTX CONSOLIDATION
107d in phase · OBV NEUTRAL
Current IV 306.5%
IV Percentile 92nd %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ANTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID BREAKDOWN
154d in phase · OBV DISTRIBUTION
Current IV 11.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $198.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $424.6M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANTX vs OVID Key Questions & Quantitative Answers

As of Nov 20, 2026, AN2 Therapeutics, Inc. (ANTX) captures the overall head-to-head institutional edge over Ovid Therapeutics Inc. (OVID) on higher Unified Composite conviction (40.5/100 SELL vs. 52.3/100 HOLD) after splitting the core matrix 3–6 (led by Options & Positioning), while OVID wins 4–1 across the 6-pillar growth and valuation breakdown. ANTX trades at $5.08 (N/M Forward P/E, 0.0% operating margin) versus OVID at $2.20 (1.8x Forward P/E, -4693.7% operating margin). Composite vs. Pillar Nuance: While OVID currently prints a higher short-term Unified Composite Score (52.3/100 HOLD vs. ANTX 40.5/100 SELL), ANTX captures the overall institutional head-to-head verdict (3–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4693.7% operating margin) and revenue trajectory (+0.0% vs. -88.3% YoY). Technical & Structure Timing Caution: ANTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 61.8); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OVID leads the Growth & Scale pillar: ANTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). On trailing 12-month operating scale, ANTX generates N/A in USD-normalized revenue versus $1.5M for OVID. In operating R&D and SG&A reinvestment, ANTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. ANTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANTX (-51.3% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ANTX carries 306.5% implied volatility (92nd %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 99% Vol realized risk). By comparison, OVID carries 11.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.04β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.